
Chronic Spontaneous Urticaria

Podcasts
Continuing Medical Education
All News
Advertisement

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
Advertisement
Advertisement






























